<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Weekly Executive Summary – CoreAxis AI</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            background: #f7f9fb;
            margin: 0;
            padding: 40px;
            color: #222;
        }
        h1, h2, h3 {
            margin-bottom: 6px;
        }
        h1 {
            font-size: 32px;
            color: #1a3c7c;
        }
        h2 {
            font-size: 26px;
            color: #274b8a;
            border-left: 6px solid #274b8a;
            padding-left: 10px;
            margin-top: 40px;
        }
        h3 {
            font-size: 20px;
            margin-top: 25px;
            color: #333;
        }
        .section {
            margin-bottom: 35px;
            padding: 20px;
            background: #fff;
            border-radius: 8px;
            box-shadow: 0 2px 6px rgba(0,0,0,0.08);
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 12px;
            background: #fff;
        }
        table th {
            background: #eef2f7;
            text-align: left;
            padding: 10px;
            font-size: 14px;
        }
        table td {
            padding: 8px 10px;
            border-bottom: 1px solid #e5e5e5;
            font-size: 14px;
        }
        .footer {
            margin-top: 60px;
            padding-top: 20px;
            font-size: 14px;
            color: #666;
            border-top: 1px solid #ccc;
        }
    </style>
</head>

<body>

<h1>Weekly Executive Summary Report</h1>
<p><strong>Date:</strong> 2025-11-22</p>
<p><strong>Total Diseases Covered:</strong> 46</p>

<!-- SECTION 1 -->
<div class="section">
    <h2>1. Portfolio Overview (One-Week Global Summary)</h2>
    <p><strong>Average Target Confidence:</strong> 0.68</p>
    <p><strong>High-Priority Targets (AI):</strong> 40</p>
    <p><strong>New High-Value Signals Detected:</strong> 20</p>
    <p><strong>Total Evidence Articles Processed:</strong> 2170000</p>
</div>

<!-- SECTION 2 -->
<div class="section">
    <h2>2. Emerging High-Value Targets (AI Priority)</h2>
    <table>
        <tr>
            <th>Disease</th>
            <th>Target</th>
            <th>Confidence</th>
            <th>Evidence Alignment</th>
            <th>DepMap Alignment</th>
            <th>Issue Flag</th>
        </tr>
        <tr><td>kidney renal clear cell carcinoma</td><td>SET</td><td>0.841</td><td>0.211</td><td>1.000</td><td>None</td></tr><tr><td>non-small cell lung cancer</td><td>MET</td><td>0.834</td><td>0.208</td><td>0.940</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>MTOR</td><td>0.831</td><td>0.214</td><td>0.906</td><td>None</td></tr><tr><td>glioblastoma</td><td>MTOR</td><td>0.830</td><td>0.206</td><td>0.906</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>STAT3</td><td>0.829</td><td>0.214</td><td>0.888</td><td>None</td></tr><tr><td>glioblastoma</td><td>STAT3</td><td>0.828</td><td>0.206</td><td>0.888</td><td>None</td></tr><tr><td>amyotrophic lateral sclerosis</td><td>SET</td><td>0.827</td><td>0.164</td><td>1.000</td><td>None</td></tr><tr><td>medulloblastoma</td><td>MTOR</td><td>0.827</td><td>0.180</td><td>0.906</td><td>None</td></tr><tr><td>kidney renal clear cell carcinoma</td><td>MTOR</td><td>0.826</td><td>0.211</td><td>0.906</td><td>None</td></tr><tr><td>medulloblastoma</td><td>STAT3</td><td>0.825</td><td>0.180</td><td>0.888</td><td>None</td></tr><tr><td>pancreatic cancer</td><td>STAT3</td><td>0.822</td><td>0.187</td><td>0.888</td><td>None</td></tr><tr><td>gastric cancer</td><td>SET</td><td>0.822</td><td>0.182</td><td>1.000</td><td>None</td></tr><tr><td>psoriasis</td><td>STAT3</td><td>0.821</td><td>0.155</td><td>0.888</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>SET</td><td>0.819</td><td>0.184</td><td>1.000</td><td>None</td></tr><tr><td>medulloblastoma</td><td>TP53</td><td>0.818</td><td>0.180</td><td>0.846</td><td>None</td></tr><tr><td>ulcerative colitis</td><td>TNF</td><td>0.818</td><td>0.149</td><td>0.897</td><td>Insufficient Evidence</td></tr><tr><td>triple-negative breast cancer</td><td>CXCR4</td><td>0.818</td><td>0.214</td><td>0.837</td><td>None</td></tr><tr><td>medulloblastoma</td><td>MYC</td><td>0.818</td><td>0.180</td><td>0.846</td><td>None</td></tr><tr><td>colorectal cancer</td><td>MTOR</td><td>0.818</td><td>0.184</td><td>0.906</td><td>None</td></tr><tr><td>non-small cell lung cancer</td><td>KRAS</td><td>0.818</td><td>0.208</td><td>0.812</td><td>None</td></tr><tr><td>liver cancer</td><td>MTOR</td><td>0.817</td><td>0.193</td><td>0.906</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>MYC</td><td>0.817</td><td>0.214</td><td>0.846</td><td>None</td></tr><tr><td>colorectal cancer</td><td>STAT3</td><td>0.816</td><td>0.184</td><td>0.888</td><td>None</td></tr><tr><td>neuroblastoma</td><td>MYC</td><td>0.815</td><td>0.156</td><td>0.846</td><td>None</td></tr><tr><td>neuroblastoma</td><td>SET</td><td>0.814</td><td>0.156</td><td>1.000</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>MET</td><td>0.814</td><td>0.214</td><td>0.940</td><td>None</td></tr><tr><td>psoriasis</td><td>TNF</td><td>0.813</td><td>0.155</td><td>0.897</td><td>None</td></tr><tr><td>ovarian cancer</td><td>STAT3</td><td>0.813</td><td>0.193</td><td>0.888</td><td>None</td></tr><tr><td>small cell lung cancer</td><td>MYC</td><td>0.812</td><td>0.172</td><td>0.846</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>BCL2</td><td>0.811</td><td>0.184</td><td>0.854</td><td>None</td></tr><tr><td>ulcerative colitis</td><td>NLRP3</td><td>0.810</td><td>0.149</td><td>0.837</td><td>Insufficient Evidence</td></tr><tr><td>sarcoma</td><td>KRAS</td><td>0.810</td><td>0.153</td><td>0.812</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>TP53</td><td>0.809</td><td>0.184</td><td>0.846</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>MYC</td><td>0.809</td><td>0.184</td><td>0.846</td><td>None</td></tr><tr><td>melanoma</td><td>BRAF</td><td>0.809</td><td>0.181</td><td>0.777</td><td>None</td></tr><tr><td>medulloblastoma</td><td>EZH2</td><td>0.809</td><td>0.180</td><td>0.777</td><td>None</td></tr><tr><td>non-small cell lung cancer</td><td>STAT3</td><td>0.808</td><td>0.208</td><td>0.888</td><td>None</td></tr><tr><td>ulcerative colitis</td><td>STAT3</td><td>0.808</td><td>0.149</td><td>0.888</td><td>Insufficient Evidence</td></tr><tr><td>non-small cell lung cancer</td><td>ALK</td><td>0.808</td><td>0.208</td><td>0.752</td><td>None</td></tr><tr><td>huntington disease</td><td>SET</td><td>0.808</td><td>0.112</td><td>1.000</td><td>Insufficient Evidence</td></tr>
    </table>
</div>

<!-- SECTION 3 -->
<div class="section">
    <h2>3. Key Disease Risk Signals</h2>
    <table>
        <tr>
            <th>Disease</th>
            <th>Signal Score</th>
            <th>Evidence Strength</th>
            <th>Relation Strength</th>
            <th>Confidence</th>
        </tr>
        <tr><td>triple-negative breast cancer</td><td>3.328</td><td>0.780</td><td>0.781</td><td>0.849</td></tr><tr><td>psoriasis</td><td>3.313</td><td>0.780</td><td>0.781</td><td>0.844</td></tr><tr><td>glioblastoma</td><td>3.310</td><td>0.780</td><td>0.781</td><td>0.843</td></tr><tr><td>alzheimer disease</td><td>3.292</td><td>0.780</td><td>0.781</td><td>0.837</td></tr><tr><td>chronic lymphocytic leukemia</td><td>3.292</td><td>0.780</td><td>0.781</td><td>0.837</td></tr><tr><td>esophageal cancer</td><td>3.284</td><td>0.780</td><td>0.781</td><td>0.835</td></tr><tr><td>spinal muscular atrophy</td><td>3.276</td><td>0.780</td><td>0.781</td><td>0.832</td></tr><tr><td>acute myeloid leukemia</td><td>3.273</td><td>0.780</td><td>0.781</td><td>0.831</td></tr><tr><td>huntington disease</td><td>3.268</td><td>0.780</td><td>0.781</td><td>0.829</td></tr><tr><td>parkinson disease</td><td>3.262</td><td>0.780</td><td>0.781</td><td>0.827</td></tr><tr><td>small cell lung cancer</td><td>3.256</td><td>0.780</td><td>0.781</td><td>0.825</td></tr><tr><td>medulloblastoma</td><td>3.250</td><td>0.780</td><td>0.781</td><td>0.823</td></tr><tr><td>melanoma</td><td>3.238</td><td>0.780</td><td>0.781</td><td>0.819</td></tr><tr><td>crohn disease</td><td>3.236</td><td>0.780</td><td>0.781</td><td>0.819</td></tr><tr><td>bladder cancer</td><td>3.222</td><td>0.780</td><td>0.781</td><td>0.814</td></tr><tr><td>gastric cancer</td><td>3.212</td><td>0.780</td><td>0.781</td><td>0.811</td></tr><tr><td>neuroblastoma</td><td>3.211</td><td>0.780</td><td>0.781</td><td>0.810</td></tr><tr><td>acute lymphoblastic leukemia</td><td>3.197</td><td>0.780</td><td>0.781</td><td>0.806</td></tr><tr><td>systemic lupus erythematosus</td><td>3.191</td><td>0.780</td><td>0.781</td><td>0.804</td></tr><tr><td>spinal muscular atrophy</td><td>3.191</td><td>0.780</td><td>0.781</td><td>0.850</td></tr><tr><td>alzheimer disease</td><td>3.177</td><td>0.780</td><td>0.781</td><td>0.846</td></tr><tr><td>pancreatic cancer</td><td>3.176</td><td>0.780</td><td>0.781</td><td>0.799</td></tr><tr><td>amyotrophic lateral sclerosis</td><td>3.175</td><td>0.780</td><td>0.781</td><td>0.798</td></tr><tr><td>sarcoma</td><td>3.172</td><td>0.780</td><td>0.781</td><td>0.797</td></tr><tr><td>rheumatoid arthritis</td><td>3.172</td><td>0.780</td><td>0.781</td><td>0.797</td></tr><tr><td>kidney renal clear cell carcinoma</td><td>3.160</td><td>0.780</td><td>0.781</td><td>0.793</td></tr><tr><td>chronic lymphocytic leukemia</td><td>3.160</td><td>0.780</td><td>0.781</td><td>0.840</td></tr><tr><td>sickle cell disease</td><td>3.158</td><td>0.780</td><td>0.781</td><td>0.793</td></tr><tr><td>duchenne muscular dystrophy</td><td>3.158</td><td>0.780</td><td>0.781</td><td>0.793</td></tr><tr><td>lassa fever</td><td>3.155</td><td>0.780</td><td>0.781</td><td>0.852</td></tr><tr><td>acute lymphoblastic leukemia</td><td>3.154</td><td>0.780</td><td>0.781</td><td>0.851</td></tr><tr><td>ulcerative colitis</td><td>3.153</td><td>0.780</td><td>0.781</td><td>0.791</td></tr><tr><td>cystic fibrosis</td><td>3.152</td><td>0.780</td><td>0.781</td><td>0.837</td></tr><tr><td>sickle cell disease</td><td>3.151</td><td>0.780</td><td>0.781</td><td>0.837</td></tr><tr><td>thalassemia major</td><td>3.151</td><td>0.780</td><td>0.781</td><td>0.790</td></tr><tr><td>spinal muscular atrophy</td><td>3.147</td><td>0.780</td><td>0.781</td><td>0.849</td></tr><tr><td>gaucher disease</td><td>3.146</td><td>0.780</td><td>0.781</td><td>0.789</td></tr><tr><td>acute myeloid leukemia</td><td>3.146</td><td>0.780</td><td>0.781</td><td>0.835</td></tr><tr><td>hemophilia a</td><td>3.145</td><td>0.780</td><td>0.781</td><td>0.788</td></tr><tr><td>cystic fibrosis</td><td>3.142</td><td>0.780</td><td>0.781</td><td>0.787</td></tr>
    </table>
</div>

<!-- SECTION 4 (FIXED) -->
<div class="section">
    <h2>4. New Drug Candidate Highlights</h2>
    <p>Top validated candidates generated by AI discovery engine.</p>

    <table>
        <tr>
            <th>Disease</th>
            <th>Target</th>
            <th>Suggestion Score</th>
            <th>Evidence Score</th>
            <th>Bioactivity Score</th>
            <th>Action</th>
            <th>Confidence</th>
        </tr>
        <tr><td>ulcerative colitis</td><td>NLRP3</td><td>4.135</td><td>39616.000</td><td>0.070</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>triple-negative breast cancer</td><td>STAT3</td><td>4.116</td><td>38429.000</td><td>0.002</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>triple-negative breast cancer</td><td>CXCR4</td><td>4.102</td><td>38429.000</td><td>0.020</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>triple-negative breast cancer</td><td>MTOR</td><td>4.061</td><td>38429.000</td><td>0.020</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>ulcerative colitis</td><td>TNF</td><td>4.024</td><td>39616.000</td><td>0.030</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>ulcerative colitis</td><td>STAT3</td><td>4.021</td><td>39616.000</td><td>0.002</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>systemic lupus erythematosus</td><td>CGAS</td><td>3.986</td><td>36745.000</td><td>0.440</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>systemic lupus erythematosus</td><td>NLRP3</td><td>3.975</td><td>36745.000</td><td>0.070</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>triple-negative breast cancer</td><td>MYC</td><td>3.972</td><td>38429.000</td><td>0.200</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>triple-negative breast cancer</td><td>CDK4</td><td>3.965</td><td>38429.000</td><td>0.007</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>psoriasis</td><td>STAT3</td><td>3.957</td><td>28494.000</td><td>0.002</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>small cell lung cancer</td><td>ALK</td><td>3.942</td><td>34350.000</td><td>0.020</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>sarcoma</td><td>BRAF</td><td>3.940</td><td>30777.000</td><td>0.020</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>sarcoma</td><td>KRAS</td><td>3.939</td><td>30777.000</td><td>0.100</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>systemic lupus erythematosus</td><td>TLR7</td><td>3.938</td><td>36745.000</td><td>0.003</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>parkinson disease</td><td>LRRK2</td><td>3.930</td><td>26801.000</td><td>0.001</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>pancreatic cancer</td><td>STAT3</td><td>3.911</td><td>25602.000</td><td>0.002</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>small cell lung cancer</td><td>MYC</td><td>3.909</td><td>34350.000</td><td>0.200</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>psoriasis</td><td>TYK2</td><td>3.904</td><td>28494.000</td><td>0.001</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>small cell lung cancer</td><td>TP53</td><td>3.900</td><td>34350.000</td><td>0.013</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>ovarian cancer</td><td>STAT3</td><td>3.892</td><td>24413.000</td><td>0.002</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>sarcoma</td><td>STS</td><td>3.886</td><td>30777.000</td><td>0.010</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>rheumatoid arthritis</td><td>TNF</td><td>3.867</td><td>29591.000</td><td>0.030</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>pancreatic cancer</td><td>KRAS</td><td>3.858</td><td>25602.000</td><td>0.100</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>neuroblastoma</td><td>LRRK2</td><td>3.853</td><td>21995.000</td><td>0.001</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>psoriasis</td><td>TNF</td><td>3.850</td><td>28494.000</td><td>0.030</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>triple-negative breast cancer</td><td>EZH2</td><td>3.839</td><td>38429.000</td><td>0.010</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>pompe disease</td><td>GAA</td><td>3.832</td><td>27306.000</td><td>0.160</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>triple-negative breast cancer</td><td>MET</td><td>3.829</td><td>38429.000</td><td>0.019</td><td>INHIBIT</td><td>0.780</td></tr><tr><td>non-small cell lung cancer</td><td>ROS1</td><td>3.820</td><td>23213.000</td><td>0.020</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>non-small cell lung cancer</td><td>KRAS</td><td>3.820</td><td>23213.000</td><td>0.100</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>medulloblastoma</td><td>PTCH1</td><td>3.814</td><td>19597.000</td><td>0.017</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>medulloblastoma</td><td>STAT3</td><td>3.814</td><td>19597.000</td><td>0.002</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>triple-negative breast cancer</td><td>PRMT1</td><td>3.814</td><td>38429.000</td><td>1.000</td><td>INHIBIT</td><td>0.800</td></tr><tr><td>small cell lung cancer</td><td>YAP1</td><td>3.811</td><td>34350.000</td><td>1.020</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>melanoma</td><td>BRAF</td><td>3.782</td><td>20782.000</td><td>0.020</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>melanoma</td><td>NRAS</td><td>3.781</td><td>20782.000</td><td>0.300</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>ulcerative colitis</td><td>TLR4</td><td>3.780</td><td>39616.000</td><td>0.010</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>non-small cell lung cancer</td><td>BRAF</td><td>3.773</td><td>23213.000</td><td>0.020</td><td>INHIBIT</td><td>0.790</td></tr><tr><td>sarcoma</td><td>TP53</td><td>3.769</td><td>30777.000</td><td>0.013</td><td>INHIBIT</td><td>0.790</td></tr>
    </table>
</div>

<!-- SECTION 5 -->
<div class="section">
    <h2>5. Evidence Trends (PubMed & Activity)</h2>
    <p><strong>Articles added this week:</strong> 3200</p>
    <p><strong>10-year drug-related filtered stream:</strong> 10-year window</p>
    <h3>Top Evidence-Growing Diseases</h3>
    <table>
        <tr>
            <th>Disease</th>
            <th>New Articles</th>
            <th>Total Evidence</th>
        </tr>
        <tr><td>covid-19</td><td>1787</td><td>—</td></tr><tr><td>esophageal cancer</td><td>1084</td><td>—</td></tr><tr><td>medulloblastoma</td><td>1083</td><td>—</td></tr><tr><td>glioblastoma</td><td>1060</td><td>—</td></tr><tr><td>colorectal cancer</td><td>1059</td><td>—</td></tr><tr><td>acute lymphoblastic leukemia</td><td>1057</td><td>—</td></tr><tr><td>liver cancer</td><td>1054</td><td>—</td></tr><tr><td>systemic lupus erythematosus</td><td>1050</td><td>—</td></tr><tr><td>crohn disease</td><td>1033</td><td>—</td></tr><tr><td>duchenne muscular dystrophy</td><td>1032</td><td>—</td></tr><tr><td>hemophilia a</td><td>1030</td><td>—</td></tr><tr><td>non-small cell lung cancer</td><td>1027</td><td>—</td></tr><tr><td>small cell lung cancer</td><td>1024</td><td>—</td></tr><tr><td>spinal muscular atrophy</td><td>1019</td><td>—</td></tr><tr><td>triple-negative breast cancer</td><td>1015</td><td>—</td></tr><tr><td>ovarian cancer</td><td>1012</td><td>—</td></tr><tr><td>gastric cancer</td><td>1006</td><td>—</td></tr><tr><td>neuroblastoma</td><td>1004</td><td>—</td></tr><tr><td>huntington disease</td><td>1003</td><td>—</td></tr><tr><td>pancreatic cancer</td><td>997</td><td>—</td></tr><tr><td>sickle cell disease</td><td>992</td><td>—</td></tr><tr><td>melanoma</td><td>988</td><td>—</td></tr><tr><td>amyotrophic lateral sclerosis</td><td>968</td><td>—</td></tr><tr><td>cystic fibrosis</td><td>963</td><td>—</td></tr><tr><td>psoriasis</td><td>954</td><td>—</td></tr><tr><td>sarcoma</td><td>954</td><td>—</td></tr><tr><td>rheumatoid arthritis</td><td>881</td><td>—</td></tr><tr><td>ebola virus disease</td><td>836</td><td>—</td></tr><tr><td>parkinson disease</td><td>826</td><td>—</td></tr><tr><td>chronic lymphocytic leukemia</td><td>817</td><td>—</td></tr>
    </table>
</div>

<!-- SECTION 6 -->
<div class="section">
    <h2>6. AI Meta-Cognition Diagnostics</h2>
    <table>
        <tr>
            <th>Disease</th>
            <th>Target</th>
            <th>Consistency</th>
            <th>Final Confidence</th>
            <th>Issues</th>
        </tr>
        <tr><td>kidney renal clear cell carcinoma</td><td>SET</td><td>0.773</td><td>0.841</td><td>None</td></tr><tr><td>non-small cell lung cancer</td><td>MET</td><td>0.763</td><td>0.834</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>MTOR</td><td>0.758</td><td>0.831</td><td>None</td></tr><tr><td>glioblastoma</td><td>MTOR</td><td>0.758</td><td>0.830</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>STAT3</td><td>0.756</td><td>0.829</td><td>None</td></tr><tr><td>glioblastoma</td><td>STAT3</td><td>0.755</td><td>0.828</td><td>None</td></tr><tr><td>amyotrophic lateral sclerosis</td><td>SET</td><td>0.753</td><td>0.827</td><td>None</td></tr><tr><td>medulloblastoma</td><td>MTOR</td><td>0.752</td><td>0.827</td><td>None</td></tr><tr><td>kidney renal clear cell carcinoma</td><td>MTOR</td><td>0.752</td><td>0.826</td><td>None</td></tr><tr><td>medulloblastoma</td><td>STAT3</td><td>0.750</td><td>0.825</td><td>None</td></tr><tr><td>pancreatic cancer</td><td>STAT3</td><td>0.746</td><td>0.822</td><td>None</td></tr><tr><td>gastric cancer</td><td>SET</td><td>0.745</td><td>0.822</td><td>None</td></tr><tr><td>psoriasis</td><td>STAT3</td><td>0.744</td><td>0.821</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>SET</td><td>0.741</td><td>0.819</td><td>None</td></tr><tr><td>medulloblastoma</td><td>TP53</td><td>0.740</td><td>0.818</td><td>None</td></tr><tr><td>ulcerative colitis</td><td>TNF</td><td>0.740</td><td>0.818</td><td>Insufficient Evidence</td></tr><tr><td>triple-negative breast cancer</td><td>CXCR4</td><td>0.740</td><td>0.818</td><td>None</td></tr><tr><td>medulloblastoma</td><td>MYC</td><td>0.740</td><td>0.818</td><td>None</td></tr><tr><td>colorectal cancer</td><td>MTOR</td><td>0.740</td><td>0.818</td><td>None</td></tr><tr><td>non-small cell lung cancer</td><td>KRAS</td><td>0.739</td><td>0.818</td><td>None</td></tr><tr><td>liver cancer</td><td>MTOR</td><td>0.739</td><td>0.817</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>MYC</td><td>0.738</td><td>0.817</td><td>None</td></tr><tr><td>colorectal cancer</td><td>STAT3</td><td>0.737</td><td>0.816</td><td>None</td></tr><tr><td>neuroblastoma</td><td>MYC</td><td>0.735</td><td>0.815</td><td>None</td></tr><tr><td>neuroblastoma</td><td>SET</td><td>0.735</td><td>0.814</td><td>None</td></tr><tr><td>triple-negative breast cancer</td><td>MET</td><td>0.734</td><td>0.814</td><td>None</td></tr><tr><td>psoriasis</td><td>TNF</td><td>0.733</td><td>0.813</td><td>None</td></tr><tr><td>ovarian cancer</td><td>STAT3</td><td>0.733</td><td>0.813</td><td>None</td></tr><tr><td>small cell lung cancer</td><td>MYC</td><td>0.731</td><td>0.812</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>BCL2</td><td>0.730</td><td>0.811</td><td>None</td></tr><tr><td>ulcerative colitis</td><td>NLRP3</td><td>0.729</td><td>0.810</td><td>Insufficient Evidence</td></tr><tr><td>sarcoma</td><td>KRAS</td><td>0.728</td><td>0.810</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>TP53</td><td>0.728</td><td>0.809</td><td>None</td></tr><tr><td>chronic lymphocytic leukemia</td><td>MYC</td><td>0.727</td><td>0.809</td><td>None</td></tr><tr><td>melanoma</td><td>BRAF</td><td>0.727</td><td>0.809</td><td>None</td></tr><tr><td>medulloblastoma</td><td>EZH2</td><td>0.727</td><td>0.809</td><td>None</td></tr><tr><td>non-small cell lung cancer</td><td>STAT3</td><td>0.726</td><td>0.808</td><td>None</td></tr><tr><td>ulcerative colitis</td><td>STAT3</td><td>0.726</td><td>0.808</td><td>Insufficient Evidence</td></tr><tr><td>non-small cell lung cancer</td><td>ALK</td><td>0.725</td><td>0.808</td><td>None</td></tr><tr><td>huntington disease</td><td>SET</td><td>0.725</td><td>0.808</td><td>Insufficient Evidence</td></tr>
    </table>
</div>

<!-- SECTION 7 -->
<div class="section">
    <h2>7. AI Forecast (Next Week)</h2>
    <p><strong>High-impact regions:</strong> Cancer / Inflammatory Disorders</p>
    <p><strong>Expected target shifts:</strong> KRAS, STAT3, TYK2 expected movement</p>
    <p><strong>Predicted new candidates:</strong> 10–15</p>

    <h3>Top 5 Diseases (Predicted Activity Increase)</h3>
    <table>
        <tr>
            <th>Disease</th>
            <th>Forecast Score</th>
            <th>Confidence</th>
        </tr>
        <tr><td>triple-negative breast cancer</td><td>3.328</td><td>0.849</td></tr><tr><td>psoriasis</td><td>3.313</td><td>0.844</td></tr><tr><td>glioblastoma</td><td>3.310</td><td>0.843</td></tr><tr><td>alzheimer disease</td><td>3.292</td><td>0.837</td></tr><tr><td>chronic lymphocytic leukemia</td><td>3.292</td><td>0.837</td></tr>
    </table>
</div>

<!-- SECTION 8 -->
<div class="section">
    <h2>8. Recommendations for Companies & Researchers</h2>
    <ul>
        <li>Prioritize high-impact inflammatory pathways</li>
        <li>Monitor STAT3/MYC clusters</li>
        <li>Evaluate TYK2 small-molecule opportunities</li>
        <li>Track DepMap-driven shifts weekly</li>
    </ul>
</div>

<div class="footer">
    <strong>CoreAxis Labs</strong><br>
    장인석<br>
    서울특별시 마포구 월드컵로 196 115<br>
    Email: research@coreaxislab.com<br><br>
    <em>Powered by CoreAxis Industrial HGNC-Based AI Pipeline</em>
</div>

</body>
</html>
